Jonathan Strober, MD, explains the initial presentation of myasthenia gravis in a pediatric patient population and why initial diagnosis for these patients can be challenging.

The primary endpoint in Vivacity-MG3 was the change in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores from baseline to the average over weeks 22, 23, and 24 in seropositive patients ...

Winnacunnet High School senior Joe Labrecque has transformed his battle with a rare chronic illness into a mission to help ...

The UK regulatory authority has cleared the path for some patients with generalised myasthenia gravis (gMG ... antibody seropositive gMG, including those who have failed, not tolerated or are ...

The approval marks the second international approval for rozanolixizumab (Rystiggo; UCB Pharma) for generalized myasthenia ...

anti-LRP4+) adults with generalised myasthenia gravis (gMG). 1, 2 Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADL b and QMG c scores over 84 ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around. Researchers have ...

Generalised myasthenia gravis (gMG) is a chronic disorder in which the body's immune system mistakenly targets the neuromuscular junctions—areas where nerves signal muscles to move. This ...

"Overall, I am encouraged by these results that show improvement in disease control as measured by the MG-ADL and QMG scores across a broad population seropositive for AChR, MuSK, or LRP4 ...